Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation.
Gespeichert in:
| Titel: | Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation. |
|---|---|
| Autoren: | Wang S; Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.; Chinese PLA Medical School, Beijing 100039, China., Yang T; Chinese PLA Medical School, Beijing 100039, China.; National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Li T; Chinese PLA Medical School, Beijing 100039, China.; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China., Shi L; Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Xu R; National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Zhang C; National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Wang Z; Chinese PLA Medical School, Beijing 100039, China., Zhang Z; Chinese PLA Medical School, Beijing 100039, China.; National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Shi M; National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Xu Z; National Clinical Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China., Wang FS; Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.; Chinese PLA Medical School, Beijing 100039, China. |
| Quelle: | Chinese medical journal [Chin Med J (Engl)] 2025 Nov 20; Vol. 138 (22), pp. 2984-2992. Date of Electronic Publication: 2025 Mar 07. |
| Publikationsart: | Journal Article; Multicenter Study |
| Sprache: | English |
| Info zur Zeitschrift: | Publisher: Chinese Medical Association ; produced by Wolters Kluwer Country of Publication: China NLM ID: 7513795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2542-5641 (Electronic) Linking ISSN: 03666999 NLM ISO Abbreviation: Chin Med J (Engl) Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2015- > : Beijing : Chinese Medical Association ; produced by Wolters Kluwer Original Publication: Peking, Chinese Medical Assn. |
| MeSH-Schlagworte: | COVID-19*/therapy , Mesenchymal Stem Cell Transplantation*/methods , Mesenchymal Stem Cell Transplantation*/adverse effects , Umbilical Cord*/cytology , Mesenchymal Stem Cells*/cytology, Humans ; Female ; Male ; Middle Aged ; Adult ; SARS-CoV-2 ; Aged ; Treatment Outcome |
| Abstract: | Background: The effects of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment on coronavirus disease 2019 (COVID-19) patients have been preliminarily characterized. However, real-world data on the safety and efficacy of intravenous transfusions of MSCs in hospitalized COVID-19 patients at the convalescent stage remain to be reported. Methods: This was a single-arm, multicenter, real-word study in which a contemporaneous external control was included as the control group. Besides, severe and critical COVID-19 patients were considered together as the severe group, given the small number of critical patients. For a total of 110 patients, 21 moderate patients and 31 severe patients were enrolled in the MSC treatment group, while 26 moderate patients and 32 severe patients were enrolled in the control group. All patients received standard treatment. The MSC treatment patients additionally received intravenous infusions of MSCs at a dose of 4 × 10 7 cells on days 0, 3, and 6, respectively. The clinical outcomes, including adverse events (AEs), lung lesion proportion on chest computed tomography, pulmonary function, 6-min walking distance (6-MWD), clinical symptoms, and laboratory parameters, were measured on days 28, 90, 180, 270, and 360 during the follow-up visits. Results: In patients with moderate COVID-19, MSC treatment improved pulmonary function parameters, including forced expiratory volume in the first second (FEV1) and maximum forced vital capacity (VCmax) on days 28 (FEV1, 2.75 [2.35, 3.23] vs . 2.11 [1.96, 2.35], P = 0.008; VCmax, 2.92 [2.55, 3.60] vs . 2.47 [2.18, 2.68], P = 0.041), 90 (FEV1, 2.93 [2.63, 3.27] vs . 2.38 [2.24, 2.63], P = 0.017; VCmax, 3.52 [3.02, 3.80] vs . 2.59 [2.45, 3.15], P = 0.017), and 360 (FEV1, 2.91 [2.75, 3.18] vs . 2.30 [2.16, 2.70], P = 0.019; VCmax,3.61 [3.35, 3.97] vs . 2.69 [2.56, 3.23], P = 0.036) compared with the controls. In addition, in severe patients, MSC treatment notably reduced the proportion of ground-glass lesions in the whole lung volume on day 90 ( P = 0.045) compared with the controls. No difference in the incidence of AEs was observed between the two groups. Similarly, no significant differences were found in the 6-MWD, D-dimer levels, or interleukin-6 concentrations between the MSC and control groups. Conclusions: Our results demonstrate the safety and potential of MSC treatment for improved lung lesions and pulmonary function in convalescent COVID-19 patients. However, comprehensive and long-term studies are required to confirm the efficacy of MSC treatment. Trial Registration: Chinese Clinical Trial Registry, ChiCTR2000031430. (Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.) |
| References: | Stem Cell Res Ther. 2022 Jul 28;13(1):365. (PMID: 35902979) EBioMedicine. 2022 Jan;75:103789. (PMID: 34963099) Am J Respir Crit Care Med. 2023 Feb 1;207(3):261-270. (PMID: 36099435) Lancet. 2021 May 29;397(10289):2049-2059. (PMID: 34000257) Aging Dis. 2020 Mar 9;11(2):216-228. (PMID: 32257537) Cytotherapy. 2006;8(4):315-7. (PMID: 16923606) J Biomed Sci. 2016 Nov 4;23(1):76. (PMID: 27809910) N Engl J Med. 2022 Apr 14;386(15):1397-1408. (PMID: 35172054) Front Immunol. 2022 Jul 04;13:932360. (PMID: 35860245) Signal Transduct Target Ther. 2021 Dec 6;6(1):414. (PMID: 34873151) Lancet Infect Dis. 2024 Aug;24(8):845-855. (PMID: 38663423) JAMA. 2020 Sep 15;324(11):1048-1057. (PMID: 32821939) Stem Cells. 2011 Jun;29(6):913-9. (PMID: 21506195) Signal Transduct Target Ther. 2020 Aug 27;5(1):172. (PMID: 32855385) Lancet Haematol. 2016 Jan;3(1):e45-52. (PMID: 26765648) Lancet. 2023 Sep 30;402(10408):1115-1117. (PMID: 37652071) Chin Med J (Engl). 2024 Dec 5;137(23):2808-2820. (PMID: 39602326) Signal Transduct Target Ther. 2021 Feb 10;6(1):58. (PMID: 33568628) Stem Cells Transl Med. 2021 May;10(5):660-673. (PMID: 33400390) Stem Cell Res Ther. 2022 Jun 28;13(1):283. (PMID: 35765103) Crit Care. 2022 Feb 21;26(1):48. (PMID: 35189925) Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. (PMID: 12091180) Stem Cell Res Ther. 2021 Jan 29;12(1):91. (PMID: 33514427) N Engl J Med. 2020 Nov 5;383(19):1827-1837. (PMID: 32459919) JAMA. 2020 Oct 6;324(13):1330-1341. (PMID: 32876694) Front Med. 2020 Oct;14(5):664-673. (PMID: 32761491) EBioMedicine. 2023 Jun;92:104600. (PMID: 37149930) Stem Cell Res Ther. 2022 Apr 1;13(1):134. (PMID: 35365239) Stem Cells Transl Med. 2022 Sep 21;11(9):900-911. (PMID: 35993521) Adv Sci (Weinh). 2020 Oct;7(19):e2001435. (PMID: 35403380) Signal Transduct Target Ther. 2021 Sep 8;6(1):339. (PMID: 34497264) Stem Cell Res Ther. 2022 Jul 16;13(1):321. (PMID: 35842684) Science. 2021 Dec 24;374(6575):1586-1593. (PMID: 34726479) Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7. (PMID: 9817683) Crit Care. 2023 Jan 20;27(1):31. (PMID: 36670442) Lancet Psychiatry. 2022 Oct;9(10):815-827. (PMID: 35987197) Nat Rev Microbiol. 2023 Mar;21(3):133-146. (PMID: 36639608) Nat Med. 2021 Apr;27(4):601-615. (PMID: 33753937) Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. (PMID: 31613151) Nature. 2020 Sep;585(7824):273-276. (PMID: 32516797) EClinicalMedicine. 2020 Aug;25:100454. (PMID: 32838232) |
| Contributed Indexing: | Keywords: Coronavirus disease 2019; Mesenchymal stem cells; Pulmonary function; Severe acute respiratory syndrome coronavirus 2 |
| Entry Date(s): | Date Created: 20250307 Date Completed: 20251120 Latest Revision: 20251123 |
| Update Code: | 20251123 |
| PubMed Central ID: | PMC12634258 |
| DOI: | 10.1097/CM9.0000000000003459 |
| PMID: | 40051040 |
| Datenbank: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Background: The effects of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment on coronavirus disease 2019 (COVID-19) patients have been preliminarily characterized. However, real-world data on the safety and efficacy of intravenous transfusions of MSCs in hospitalized COVID-19 patients at the convalescent stage remain to be reported.<br />Methods: This was a single-arm, multicenter, real-word study in which a contemporaneous external control was included as the control group. Besides, severe and critical COVID-19 patients were considered together as the severe group, given the small number of critical patients. For a total of 110 patients, 21 moderate patients and 31 severe patients were enrolled in the MSC treatment group, while 26 moderate patients and 32 severe patients were enrolled in the control group. All patients received standard treatment. The MSC treatment patients additionally received intravenous infusions of MSCs at a dose of 4 × 10 7 cells on days 0, 3, and 6, respectively. The clinical outcomes, including adverse events (AEs), lung lesion proportion on chest computed tomography, pulmonary function, 6-min walking distance (6-MWD), clinical symptoms, and laboratory parameters, were measured on days 28, 90, 180, 270, and 360 during the follow-up visits.<br />Results: In patients with moderate COVID-19, MSC treatment improved pulmonary function parameters, including forced expiratory volume in the first second (FEV1) and maximum forced vital capacity (VCmax) on days 28 (FEV1, 2.75 [2.35, 3.23] vs . 2.11 [1.96, 2.35], P = 0.008; VCmax, 2.92 [2.55, 3.60] vs . 2.47 [2.18, 2.68], P = 0.041), 90 (FEV1, 2.93 [2.63, 3.27] vs . 2.38 [2.24, 2.63], P = 0.017; VCmax, 3.52 [3.02, 3.80] vs . 2.59 [2.45, 3.15], P = 0.017), and 360 (FEV1, 2.91 [2.75, 3.18] vs . 2.30 [2.16, 2.70], P = 0.019; VCmax,3.61 [3.35, 3.97] vs . 2.69 [2.56, 3.23], P = 0.036) compared with the controls. In addition, in severe patients, MSC treatment notably reduced the proportion of ground-glass lesions in the whole lung volume on day 90 ( P = 0.045) compared with the controls. No difference in the incidence of AEs was observed between the two groups. Similarly, no significant differences were found in the 6-MWD, D-dimer levels, or interleukin-6 concentrations between the MSC and control groups.<br />Conclusions: Our results demonstrate the safety and potential of MSC treatment for improved lung lesions and pulmonary function in convalescent COVID-19 patients. However, comprehensive and long-term studies are required to confirm the efficacy of MSC treatment.<br />Trial Registration: Chinese Clinical Trial Registry, ChiCTR2000031430.<br /> (Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.) |
|---|---|
| ISSN: | 2542-5641 |
| DOI: | 10.1097/CM9.0000000000003459 |